logo

Dynavax Technologies Corp (DVAX)



Trade DVAX now with
  Date
  Headline
2/21/2018 9:38:14 AM Dynavax’s HEPLISAV-B Recommended By CDC Panel On Immunization Practices For Prevention Of Hepatitis B In Adults
1/9/2018 6:06:39 AM Hercules Capital Achieves More Than $880 Mln In New Commitments In 2017
1/8/2018 6:09:18 AM Dynavax Reports Availability Of HEPLISAV-B In The US For Prevention Of Hepatitis B In Adults
12/7/2017 10:48:10 PM New Drugs Approved In November
11/9/2017 4:50:35 PM Dynavax Reports FDA Approval Of HEPLISAV-B For Prevention Of Hepatitis B In Adults
11/3/2017 6:40:45 AM Dynavax Technologies Q3 Net Loss Narrows To $22.1 Mln Or $0.38/shr From $34.7 Mln Or $0.90/shr Last Year
9/25/2017 8:59:27 AM RBC Capital Markets Is Raising Dynavax Technologies Corp (DVAX) 4Q18 Estimate To -0.58 From -0.60
9/25/2017 8:59:08 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 3Q18 Estimate To -0.60 From -0.58
9/25/2017 8:58:53 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 2Q18 Estimate To -0.56 From -0.54
9/25/2017 8:58:40 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 1Q18 Estimate To -0.52 From -0.51
9/25/2017 8:58:26 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 4Q17 Estimate To -0.48 From -0.45
9/25/2017 8:58:09 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 3Q17 Estimate To -0.44 From -0.33
9/25/2017 8:57:53 AM RBC Capital Markets Is Raising Dynavax Technologies Corp (DVAX) 2017 Estimate To -1.08 From -1.57
9/25/2017 8:57:35 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 2018 Estimate To -2.27 From -2.23
9/25/2017 8:57:18 AM RBC Capital Markets Is Cutting Dynavax Technologies Corp (DVAX) 2017 Estimate To -1.92 From -1.78